FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967571569> ?p ?o ?g. }

• W2967571569 abstract "In myelodysplastic/myeloproliferative neoplasms (MDS/MPN) with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), somatic mutation in the Splicing Factor 3B subunit 1 gene (SF3B1) at the rate of approximately 85% was concurrently found with one of the MPN driver mutations, such as JAK2 V617F (50%), calreticulin (CALR) exon 9 (1–3%) and MPL W515 (0–3%) mutations (Patnaik and Tefferi 2017). Impaired erythropoiesis induced by mutant SF3B1 (Mupo et al, 2017, Obeng et al, 2016), and an increase in one or more lineages of blood cells induced by MPN driver mutations (Vainchenker and Kralovics 2017) have led to the notion that the overlapping phenotypes of MDS/MPN are at least partly, if not totally, due to overlapping disease-defining mutations (Cazzola et al, 2013). The MPN driver mutation, JAK2 exon 12, is rare in MPN and has been exclusively found in polycythaemia vera (PV) (Scott 2011), with no reports of this mutation in MDS/MPN-RS-T to date. A bone marrow biopsy of a patient, who was originally followed for Raynaud disease in our hospital and presented with anaemia associated with persistent leucocytosis and thrombocytosis (Fig S1 and Table SI), displayed MDS/MPN features (Fig S2) and lacked any chromosomal abnormality, including Philadelphia chromosome; the patient was thus suspected to have MDS/MPN-RS-T. Sequence analysis (see Data S1) of genomic DNA obtained from a peripheral blood sample revealed the allelic frequencies of SF3B1 E622D, JAK2 H538_K539delinsL (hereinafter called JAK2 exon 12, one of the typical mutations of JAK2 exon 12; Scott 2011), and TET2 I1873T (Fig S3) to be 44%, 75% and 14%, respectively. Based on this evidence, the patient was diagnosed with MDS/MPN-RS-T. As no report on the identification of JAK2 exon 12 mutation in MDS/MPN-RS-T was available, and only limited assessment has been performed for the capacity of haematopoietic cell differentiation in MDS/MPN-RS-T harbouring SF3B1 and MPN driver mutations, we examined the colony-forming ability of the patient's bone marrow mononuclear cells (BM-MNCs). Unlike BM-MNCs obtained from a patient with PV harbouring JAK2 exon 12 mutation and a patient with malignant lymphoma without bone marrow infiltration (hereinafter called control), those from the patient with MDS/MPN-RS-T formed smaller colonies of burst-forming unit-erythroid (BFU-E), colony-forming unit-granulocyte (CFU-G), CFU-macrophage (CFU-M), and CFU–granulocyte, macrophage (CFU-GM) (Fig 1A). Significantly lower number of BFU-Es was formed from BM-MNCs of the MDS/MPN-RS-T samples than from the PV and control samples, even in the presence of erythropoietin (EPO) (Fig 1B). EPO-independent BFU-Es were formed only in those with PV but not in those with MDS/MPN-RS-T harbouring JAK2 exon 12 mutation (Fig 1B), confirming that the patient had neither PV nor post-PV myelofibrosis. Based on the mutation status in individual colonies (Fig 1C and S3) determined by Sanger sequencing (see Data S1), diagrams were created to represent a hypothetical clonal evolution of haematopoietic progenitor cells (Fig 2A,2B). As expected from the patient's anaemic phenotype, an acquisition of SF3B1 mutation occurred earlier than any other mutation. JAK2 exon 12 mutation was always concurrently detected with the SF3B1 mutation, implying that BFU-E formation was blocked by mutant SF3B1, leading to anaemia in the patient, regardless of JAK2 exon 12 mutation. In contrast, in MPN, acquisition of SF3B1 mutation seems to be a later event (Boiocchi et al, 2019). Therefore, we hypothesized that the order of acquisition of SF3B1 mutation and an MPN driver mutation is likely to define the disease type (Fig 2C). Seventeen out of 28 BFU-Es (60.7%) were defined as wild-type (Fig 2A), which is contradictory to the anaemic phenotype of our patient. This discrepancy is presumably owing to the weakened capacity of erythroid cell differentiation in progenitor cells, considering the smaller size of BFU-Es, regardless of SF3B1 and JAK2 exon 12 mutations (Fig 1A). In contrast to the BFU-E formation, the ratio of wild-type (n = 4, 16.0%) versus SF3B1 mutant (n = 21, 84.0%) in CFU-G/M/GMs was significantly reduced compared to that in BFU-Es (P < 0.001, Table SII). This suggests skewing of the progenitor cells harbouring the SF3B1 mutation toward the myeloid lineage. Although the leucocytosis-like phenotype was not recapitulated in the colony assay, these genetic analyses implied that SF3B1 mutation, in combination with JAK2 exon 12 mutation, contributed to the leucocytosis in the patient by skewing the haematopoietic lineage towards myeloid (Fig 1C). Although this needs to be confirmed with bone marrow cells from multiple patients, it definitely suggests the possibility of cell extrinsic factor(s), such as cytokines and the bone marrow niche, playing a key role in the induction of leucocytosis in the patient with MDS/MPN-RS-T. Screening for JAK2 exon 12 mutations may not be routinely performed in daily clinical practice. The identification of concurrent SF3B1 mutation and MPN driver mutation supports the diagnosis of MDS/MPN-RS-T, the prognosis of which is different and treatment options vary across MDS or MPN. We would like to emphasize the importance of analysing JAK2 exon 12 mutation in patients with suspected MDS/MPN-RS-T, but who are negative for JAK2 V617F, CALR exon 9 and MPL W515 mutations. Furthermore, we would like to note that MDS/MPN-RS-T might often be misdiagnosed as essential thrombocythaemia (ET) or prefibrotic/early primary myelofibrosis (pre-PMF), especially when the bone marrow assessment, such as iron staining, is not properly performed. Detection of SF3B1 mutation does not support diagnosis, because this occurs in 5% of ET and 10% of PMF cases (Tefferi et al, 2016a, Tefferi et al, 2016b). A mild anaemia and megakaryocytic dysplasia are associated with pre-PMF. Therefore, we would like to emphasize that the absence or small number, if any, of ring sideroblasts and that of erythroid dysplasia should be confirmed in patients suspected with ET and pre-PMF, especially when they harbour SF3B1 mutation. In summary, we identified a patient with MDS/MPN-RS-T harboring SF3B1 and JAK2 exon 12 mutations. Considering the possibility that the order of acquisition of SF3B1 mutation and an MPN driver mutation defines the disease type, this study highlighted the importance of a comprehensive assessment of gene alterations, as well as pathology, for the diagnosis of MPN and MDS/MPN-RS-T. We thank the members of the Department of Haematology, Juntendo University Graduate School of Medicine for encouraging this study. TI designed the study, carried out the experiment, and wrote the initial draft of the manuscript. MA, YH and NK contributed to manuscript preparation, analysis and interpretation of data. MI performed histological diagnosis of clinical samples. SJ, HN, TO, KM, YF contributed to data collection. MI, YE, AO, NK supervised the study. This work was funded in part by the MEXT's Promotion Plan for the Platform of Human Resource Development for Cancer Project; the JSPS KAKENHI Grant (#17K16195); and Grant for Cross-disciplinary Collaboration in Juntendo University (#30-8). The funders had no role in manuscript preparation. Data S1. Patients and methods. Figure S1. Progressive leukocytosis, thrombocytosis, and anemia observed in the patient. Figure S2. Bone marrow morphologies of the patient harboring JAK2 exon 12 mutation, representing features associated with MDS/MPN-RS-T. Figure S3. Detection of SF3B1, JAK2 exon 12, and TET2 mutations in peripheral blood and colonies by Sanger sequencing. Table SI. Hematological and biochemical data for the patient with MDS/MPN-RS-T harboring JAK2 exon 12 mutation at initial diagnosis. Table SII. Enrichment of mutant cells in myeloid lineages. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W2967571569 created "2019-08-22" @default.
• W2967571569 creator A5010974644 @default.
• W2967571569 creator A5013650859 @default.
• W2967571569 creator A5031116384 @default.
• W2967571569 creator A5046272391 @default.
• W2967571569 creator A5048349351 @default.
• W2967571569 creator A5056066788 @default.
• W2967571569 creator A5056984470 @default.
• W2967571569 creator A5064118324 @default.
• W2967571569 creator A5071399205 @default.
• W2967571569 creator A5072628046 @default.
• W2967571569 creator A5075966205 @default.
• W2967571569 creator A5077593817 @default.
• W2967571569 creator A5090844243 @default.
• W2967571569 date "2019-08-16" @default.
• W2967571569 modified "2023-09-30" @default.
• W2967571569 title "<i>JAK2</i> exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera" @default.
• W2967571569 cites W2028390656 @default.
• W2967571569 cites W2045876806 @default.
• W2967571569 cites W2511911618 @default.
• W2967571569 cites W2520178460 @default.
• W2967571569 cites W2557590973 @default.
• W2967571569 cites W2558736960 @default.
• W2967571569 cites W2564597498 @default.
• W2967571569 cites W2586125700 @default.
• W2967571569 cites W2906853118 @default.
• W2967571569 doi "https://doi.org/10.1111/bjh.16146" @default.
• W2967571569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31418453" @default.
• W2967571569 hasPublicationYear "2019" @default.
• W2967571569 type Work @default.
• W2967571569 sameAs 2967571569 @default.
• W2967571569 citedByCount "8" @default.
• W2967571569 countsByYear W29675715692020 @default.
• W2967571569 countsByYear W29675715692021 @default.
• W2967571569 countsByYear W29675715692022 @default.
• W2967571569 countsByYear W29675715692023 @default.
• W2967571569 crossrefType "journal-article" @default.
• W2967571569 hasAuthorship W2967571569A5010974644 @default.
• W2967571569 hasAuthorship W2967571569A5013650859 @default.
• W2967571569 hasAuthorship W2967571569A5031116384 @default.
• W2967571569 hasAuthorship W2967571569A5046272391 @default.
• W2967571569 hasAuthorship W2967571569A5048349351 @default.
• W2967571569 hasAuthorship W2967571569A5056066788 @default.
• W2967571569 hasAuthorship W2967571569A5056984470 @default.
• W2967571569 hasAuthorship W2967571569A5064118324 @default.
• W2967571569 hasAuthorship W2967571569A5071399205 @default.
• W2967571569 hasAuthorship W2967571569A5072628046 @default.
• W2967571569 hasAuthorship W2967571569A5075966205 @default.
• W2967571569 hasAuthorship W2967571569A5077593817 @default.
• W2967571569 hasAuthorship W2967571569A5090844243 @default.
• W2967571569 hasBestOaLocation W29675715691 @default.
• W2967571569 hasConcept C104317684 @default.
• W2967571569 hasConcept C126322002 @default.
• W2967571569 hasConcept C170493617 @default.
• W2967571569 hasConcept C2778740236 @default.
• W2967571569 hasConcept C2778837598 @default.
• W2967571569 hasConcept C2779788118 @default.
• W2967571569 hasConcept C2780007613 @default.
• W2967571569 hasConcept C2780076729 @default.
• W2967571569 hasConcept C2781107747 @default.
• W2967571569 hasConcept C2909272587 @default.
• W2967571569 hasConcept C2910274570 @default.
• W2967571569 hasConcept C32465701 @default.
• W2967571569 hasConcept C36823959 @default.
• W2967571569 hasConcept C501734568 @default.
• W2967571569 hasConcept C502942594 @default.
• W2967571569 hasConcept C54355233 @default.
• W2967571569 hasConcept C71924100 @default.
• W2967571569 hasConcept C86803240 @default.
• W2967571569 hasConcept C89560881 @default.
• W2967571569 hasConceptScore W2967571569C104317684 @default.
• W2967571569 hasConceptScore W2967571569C126322002 @default.
• W2967571569 hasConceptScore W2967571569C170493617 @default.
• W2967571569 hasConceptScore W2967571569C2778740236 @default.
• W2967571569 hasConceptScore W2967571569C2778837598 @default.
• W2967571569 hasConceptScore W2967571569C2779788118 @default.
• W2967571569 hasConceptScore W2967571569C2780007613 @default.
• W2967571569 hasConceptScore W2967571569C2780076729 @default.
• W2967571569 hasConceptScore W2967571569C2781107747 @default.
• W2967571569 hasConceptScore W2967571569C2909272587 @default.
• W2967571569 hasConceptScore W2967571569C2910274570 @default.
• W2967571569 hasConceptScore W2967571569C32465701 @default.
• W2967571569 hasConceptScore W2967571569C36823959 @default.
• W2967571569 hasConceptScore W2967571569C501734568 @default.
• W2967571569 hasConceptScore W2967571569C502942594 @default.
• W2967571569 hasConceptScore W2967571569C54355233 @default.
• W2967571569 hasConceptScore W2967571569C71924100 @default.
• W2967571569 hasConceptScore W2967571569C86803240 @default.
• W2967571569 hasConceptScore W2967571569C89560881 @default.
• W2967571569 hasFunder F4320320912 @default.
• W2967571569 hasFunder F4320323395 @default.
• W2967571569 hasFunder F4320334764 @default.
• W2967571569 hasIssue "1" @default.
• W2967571569 hasLocation W29675715691 @default.
• W2967571569 hasLocation W29675715692 @default.
• W2967571569 hasOpenAccess W2967571569 @default.
• W2967571569 hasPrimaryLocation W29675715691 @default.
• W2967571569 hasRelatedWork W2081429895 @default.
• W2967571569 hasRelatedWork W2101998843 @default.

• next